IL2 and neoplasm: Consistently, in vivo neutralization of IL-2 alongside Treg depletion abrogates the induction of IFNγ+ γδ T cell responses, whereas administration of an IL-2Rβγc agonist circumvents Treg-mediated suppression and enhances tumor control.